Transporters
Application of Receiver Operating Characteristics to Assess Digoxin Drug Interaction Potential
Caroline A. Lee, Pfizer Inc.;
Joseph Bentz, Drexel University;
Michael O'Connor, Drexel University;
Johan Palm, AstraZeneca;
Harma Ellens, GlaxoSmithKline;
Krisztina Heredi-Szabo, SOLVO Biotechnology;
Dallas Bednarczyk, Novartis;
Mitchell Taub, Boehringer-Ingelheim Pharmaceuticals, Inc.;
Elke S. Perloff, BD Biosciences;
Christoph Funk, Hoffmann-La Roche Ltd;
Praveen Balimane, Bristol-Myers Squibb;
Laurent Salphati, Genentech Inc.;
Ailan Guo, Hoffmann-La Roche Inc.;
Lalitha Podila, Boehringer Ingelheim Pharmaceuticals, Inc.;
Imad Hanna, Novartis Institutes for BioMedical Research Inc.;
Cindy Xia, Millennium Pharmaceuticals, Inc.;
Libin Li, Absorption Systems LP;
Guangqing Xiao, Biogen Inc;
Heleen M. Wortelboer, TNO Quality of Life;
Dietmar Weitz, Sanofi-Aventis;
Youngeen A. Pak, Eli Lilly and Company;
Eric Reyner, Pfizer Global Research & Development;
Jesse Taur, Eisai;
Xiaoyan Chu, Merck & Co Inc-Merck Rsch Lab;
Ulrike Gradhand, Merck KGaA;
Mark Warren, Optivia;
Ganesh Rajaraman, Life Technologies - CellzDirect;
Lei Zhang, U.S. Food and Drug Administration
Automated 96-Well Assay for the Assessment of Passive Permeability and P-gp Efflux During CNS Drug Discovery
Colin Lorenzten, Elan Pharmaceuticals;
Shawn Gauby, Elan Pharmaceuticals;
David Nakamura, Elan Pharmaceuticals;
Heather Zhang, Elan Pharmaceuticals;
Erich Goldbach, Elan Pharmaceuticals;
Shaila Hoque, Elan Pharmaceuticals;
Bhushan Samant, Elan Pharmaceuticals;
Pamela Santiago, Elan Pharmaceuticals;
Patrick Rudewicz, Elan Pharmaceuticals;
John-Michael Sauer, Elan Pharmaceuticals;
George Tonn, Elan Pharmaceuticals;
Kevin Quinn, Elan Pharmaceuticals
Comparison of Digoxin Efflux Inhibition in Caco-2 and MDR1-LLC-PK1 Cell Monolayers
Elke S. Perloff, BD GentestSM Contract Research Services;
Andrew K Mason, BD GentestSM Contract Research Services;
Sudarshan Kapadnis, BD GentestSM Contract Research Services;
Wendy Khun, BD GentestSM Contract Research Services;
Lisa G Fox, BD GentestSM Contract Research Services;
David M. Stresser, BD GentestSM Contract Research Services
Digoxin is not a Substrate for Organic Anion Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but is a Substrate for a Sodium Dependent Transporter Expressed in HEK293 Cells
Mitchell E. Taub, Boehringer Ingelheim Pharmaceuticals, Inc.;
Kirsten Mease, Boehringer Ingelheim Pharmaceuticals, Inc.;
Rucha S. Sane, Boehringer Ingelheim Pharmaceuticals, Inc.;
Cory A. Watson, GlaxoSmithKline;
Liangfu Chen, GlaxoSmithKline;
Harma Ellens, GlaxoSmithKline;
Brad Hirakawa, Pfizer Global Research & Development;
Eric L. Reyner, Pfizer Global Research & Development;
Márton Jani, SOLVO Biotechnology;
Caroline A. Lee, Independent
Effects of Protein Binding on Transporter Inhibitions
Qing Zhu, Millennium Pharmaceuticals, Inc.;
Mingxiang Liao, Millennium Pharmaceuticals, Inc.;
Bei-Ching Chuang, Millennium Pharmaceuticals, Inc.;
Suresh K. Balani, Millennium Pharmaceuticals, Inc.;
Cindy Xia, Millennium Pharmaceuticals, Inc.
Human Organic Transporter 1(hOAT1) Affected the Renal Tubular Secretion of Antofloxacin
Kehua Shao, Institute of Clinical Pharmaclogy, Peking University;
Minji Wei, Institute of Clinical Pharmaclogy, Peking University;
Xiuli Zhao, Base for Clinical Trial, Tongren Hospital, Capital Medical University;
Chao Jia, Base for Clinical Trial, Tongren Hospital, Capital Medical University
Interaction of Milk with the Intestinal PEPT1-mediated Absorption of Oseltamivir in Rats and Humans
Kaori Morimoto, Takasaki University of Health and Welfare;
Kozue Kishimura, Takasaki University of Health and Welfare;
Megumi Tosaka, Takasaki University of Health and Welfare;
Hideaki Asamizu, Takasaki University of Health and Welfare;
Takaaki Nagami, Takasaki University of Health and Welfare;
Nao Kodama, Takasaki University of Health and Welfare;
Takashi Kano, Takasaki University of Health and Welfare;
Ikumi Tamai, Kanazawa University;
Takuo Ogihara, Takasaki University of Health and Welfare
Interaction of penciclovir with renal drug transporters
Adrienne Natrillo, Novartis Institutes for BioMedical Research Inc.;
Arpine Vapurcuyan, Novartis Institutes for BioMedical Research Inc.;
Yaofeng Cheng, Novartis Institutes for BioMedical Research Inc.;
Ryan Pelis, Novartis Institutes for BioMedical Research Inc.
Interactions of FTY720 and FTY720-P with ATP-binding Cassette Transporters
Joy Wang, Massachusetts College of Pharmacy and Health Science;
Eric Sands, BiogenIdec;
Cheryl Black, BiogenIdec;
David Williams, Massachusetts College of Pharmacy and Health Science;
Monica Chuong, Massachusetts College of Pharmacy and Health Science;
Eman Atef, Massachusetts College of Pharmacy and Health Science;
Barbara LeDuc, Massachusetts College of Pharmacy and Health Science;
Lawrence Gan, BiogenIdec;
Guangqing Xiao, BiogenIdec
Interactions of Selected Antivirals with Human Organic Anion Transporter 1 In Vitro and Potential Influence of Drug Competitors
Jana Mandikova, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove;
Zbynek Novy, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove;
Marie Volkova, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove;
Petr Pavek, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove;
Frantisek Trejtnar, Charles University in Prague, Faculty of Pharmacy in Hradec Kralove
Involvement of P-glycoprotein in the Brain Distribution of Blonanserin
Tomoko Inoue, Dainippon Sumitomo Pharma Co., Ltd.;
Masaaki Tagawa, Dainippon Sumitomo Pharma Co., Ltd.;
Kenichi Osada, St. Marianna University School of Medicine;
Yuriko Ogawa, St. Marianna University School of Medicine;
Toshihisa Haga, St. Marianna University School of Medicine;
Yoshihisa Sogame, Dainippon Sumitomo Pharma Co., Ltd.;
Takashi Katsumata, Dainippon Sumitomo Pharma Co., Ltd.;
Noboru Yamaguchi, St. Marianna University School of Medicine;
Masashi Yabuki, Dainippon Sumitomo Pharma Co., Ltd.
Loxapine P-glycoprotein interactions in vitro
Andrea Reed, Alexza Pharmaceuticals Inc;
Elke Perloff, BD Sioscis;
Keith Huie, Alexza Pharmaceuticals Inc;
Lori H. Takahashi, Alexza Pharmaceuticals Inc;
James Cassella, Alexza Pharmaceuticals Inc
PET Imaging of P-glycoprotein Inhibition at the Human Blood-Brain Barrier by Quinidine
Li Liu, University of Washington;
Ann C. Collier, University of Washington;
Jeanne M. Link, University of Washington;
Karen B. Domino, University of Washington;
David A. Mankoff, University of Washington;
Janet F. Eary, University of Washington;
Peng Hsiao, University of Washington;
Anand K. Deo, University of Washington;
Jashvant D. Unadkat, University of Washington
Transporter-based in vitro-in vivo extrapolation (IVIVE)
Viera Lukacova, Simulations Plus Inc.;
Michael B. Bolger, Simulations Plus Inc.;
Walter Woltosz, Simulations Plus Inc.;
Neil Parrott, F.Hoffmann-La Roche Ltd.;
Agnčs Poirier, Hoffmann-La Roche Ltd;
Thierry Lavé, Hoffmann-La Roche Ltd
![[ Visit Client Website ]](images/banner.gif)